Editas
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11 Hurley St, Cambridge, Massachusetts, ...Phone Number
(617) 401-9000Website
www.editasmedicine.comRevenue
$47 MillionStock Symbol
EDITIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
3
3
1
1
2
2
About Editas
Editas Medicine is a genome editing company focused on translating the power and potential of genome editing systems into a pipeline of medicines for people living with serious diseases. Editas is headquartered in Cambridge, Massachusetts with a site in Boulder, Colorado.Explore more
Editas Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Editas your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Editas has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Editas, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Editas
Click to see if Editas had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Editas has new funding data
Product Launch: Get notified when Editas launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Editas recently announced quarterly report
Check out if Editas is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Editas as Masked Content
Find 2 more new buyers
Compare Similar Companies to Editas
Compare insights from companies similar to Editas, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Editas is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Editas is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Editas.
Editas financials insights
Gather financial insights about Editas, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$43M
2015
Series B
$120M
2016
Stock Offering
$94.4M
Editas Tech Stack
A closer look at the technologies used by Editas
See more technologies
Most Recent Scoops
Open Position
Project
Editas has reported preclinical data showing that a single dose of EDIT-401 achieved greater than 90% mean reductions in LDL-C in non-human primates, with durable lowering sustained through approximately six months, alongside approximately 90% mean reductions in ApoB and Lp(a), additional key cardiovascular risk factors. The data also support a promising safety and delivery profile for the therapy.
Open Position
Open Position
Hiring Plans
Hiring Plans
Editas News & Media
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinicCRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will now present at the 2026 Jefferies Global Healthcare Conference at 2:00 p.m. ET on Thursday, June 4, 2026.Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock and accompanying common stock warrant are bei
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Editas
Sign Up For FreeTo access detailed company insights
Editas Medicine is a genome editing company focused on translating the power and potential of genome editing systems into a pipeline of medicines for people living with serious diseases. Editas is headquartered in Cambridge, Massachusetts with a site in Boulder, Colorado.... Read More
